Innovent Biologics (HK:1801) has released an update.
Innovent Biologics, Inc. has reported a remarkable 50% year-over-year growth in product revenue for the second quarter of 2024, exceeding RMB 2.0 billion. This growth is attributed to the company’s diversified portfolio and market reach, with key products such as TYVYT (sintilimab injection) showing strong sales momentum. The company’s future outlook is bolstered by a robust pipeline of approved products, assets under review, and multiple molecules in clinical studies, aiming to sustain long-term growth in oncology and general biomedicine.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
